Mary Crowley Cancer Research

Dallas, Texas 75521

22 studies enrolling now · 116 studies all time

What they study most

ARID1A Gene Mutation, Acinar Cell Carcinoma, Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Adenocarcinoma - Gastroesophageal Junction (GEJ), Adenocarcinoma of Lung, Adenocarcinoma of the Prostate, Adenocarcinoma of the Stomach, Advanced Breast Cancer, Advanced Cancer, Advanced Cancers Associated With Mesothelin Expression, Advanced Gastric Cancer

Studies at this site

• Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) — Recruiting now
• Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors — Recruiting now
• A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors — Recruiting now
• A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer — Recruiting now
• Dabrafenib and/or Trametinib Rollover Study — Recruiting now
• Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer — Recruiting now
• HF158K1 in Patients With HER-2 Expressing Advanced Solid Tumors — Recruiting now
• A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain Metastases — Recruiting now
• BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia — Recruiting now
• A Phase 1/1b Study of IAM1363 in HER2 Cancers — Recruiting now
• Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS — Recruiting now
• A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors — Recruiting now
• A Study of VET3-TGI in Patients With Solid Tumors — Recruiting now
• Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer. — Recruiting now
• Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors — Recruiting now
• Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors — Recruiting now
• A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation — Recruiting now
• Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors — Recruiting now
• Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01) — Recruiting now
• JAB-2485 Activity in Adult Patients With Advanced Solid Tumors — Recruiting now
• A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors — Recruiting now
• A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors — Recruiting now
• A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer — Recruiting now
• A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors — Recruiting now
• Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors — Recruiting now
• BP1001-A in Patients With Advanced or Recurrent Solid Tumors — Recruiting now
• A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors — Recruiting now
• Study Of ATRN-119 In Patients With Advanced Solid Tumors — Completed
• XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer — Completed
• Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01) — Running, not enrolling
• A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer — Completed
• A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2) — Running, not enrolling
• A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors — Running, not enrolling
• A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumors — Running, not enrolling
• A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors — Running, not enrolling
• Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors — Completed
• A Study of CLSP 5282 in HLA-A*03:01 Positive Adult Patients With Solid Tumors (SENTINEL-101) — Starting soon
• Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-Small Lung Cancer — Stopped early
• A Study of ASP1012 in Adults With Solid Tumors — Stopped early
• S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers — Completed
• COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies — Completed
• Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01) — Running, not enrolling
• Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies — Completed
• A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function — Stopped early
• A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors — Completed
• Combination Study of SV-BR-1-GM With Retifanlimab — Completed
• A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors — Running, not enrolling
• A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor — Running, not enrolling
• Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05) — Completed
• NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors — Completed